Chloromycetin: Potent Broad-Spectrum Antibiotic Therapy
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.75 | $44.72 (0%) | 🛒 Add to cart |
| 90 | $0.68 | $67.08 $61.06 (9%) | 🛒 Add to cart |
| 120 | $0.65 | $89.44 $78.26 (12%) | 🛒 Add to cart |
| 270 | $0.59 | $201.24 $159.10 (21%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $268.32 $208.12 (22%) | 🛒 Add to cart |
Similar products
Chloromycetin (chloramphenicol) is a bacteriostatic antibiotic with a distinguished history in clinical practice, renowned for its efficacy against a wide range of gram-positive and gram-negative bacteria, including anaerobic organisms and certain rickettsiae. Its ability to penetrate tissues and body fluids—including the central nervous system and eyes—makes it a critical agent in treating severe systemic infections where other antibiotics may fail. While its use is reserved for serious infections due to potential hematologic toxicity, it remains an indispensable tool in specific clinical scenarios under careful medical supervision. This comprehensive guide details its pharmacological profile, appropriate usage, and essential safety information for healthcare professionals.
Features
- Active ingredient: Chloramphenicol
- Available forms: Oral capsules, ophthalmic preparations, topical formulations
- Mechanism: Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit
- Spectrum: Broad activity against gram-positive and gram-negative bacteria, anaerobes, rickettsiae, and chlamydia
- Bioavailability: Excellent tissue penetration, including CSF and ocular fluids
- Stability: Stable in both acidic and alkaline environments
Benefits
- Provides reliable bactericidal activity against multidrug-resistant organisms in critical infections
- Achieves therapeutic concentrations in hard-to-penetrate tissues including the brain and intraocular spaces
- Offers flexible administration routes including oral, topical, and ophthalmic formulations
- Demonstrates rapid onset of action in life-threatening infections like meningitis and typhoid fever
- Serves as an alternative treatment for patients with penicillin or sulfonamide allergies in specific indications
- Maintains efficacy against anaerobic infections, particularly in abdominal and pelvic contexts
Common use
Chloromycetin is primarily indicated for serious infections caused by susceptible organisms when less potentially dangerous therapeutic agents are ineffective or contraindicated. Its principal applications include treatment of typhoid fever caused by Salmonella typhi, bacterial meningitis caused by Haemophilus influenzae, and serious rickettsial infections such as Rocky Mountain spotted fever. In ophthalmology, it is used for superficial ocular infections involving the conjunctiva and cornea. Topical formulations are employed for skin infections and otitis externa. It is also utilized for anaerobic infections, particularly intra-abdominal abscesses and pelvic inflammatory disease involving Bacteroides fragilis. Due to the risk of serious adverse effects, its use is typically restricted to situations where culture and sensitivity testing confirm susceptibility and where alternative antibiotics cannot be used.
Dosage and direction
Dosage must be individualized based on the severity of infection, susceptibility of the causative organism, and patient-specific factors including hepatic and renal function. For adults with serious systemic infections, the typical oral dosage ranges from 50-100 mg/kg/day divided into 4 equal doses, not to exceed 4 grams daily. For typhoid fever, 50 mg/kg/day in divided doses is standard. In meningeal infections, higher doses of 75-100 mg/kg/day may be required due to adequate CSF penetration. Pediatric dosing should be carefully calculated based on body weight, with monitoring of serum concentrations when possible. Ophthalmic preparations are typically administered as 1-2 drops in the affected eye every 3-6 hours. Treatment duration should be the shortest effective period, generally not exceeding 2 weeks for systemic administration. Complete the full prescribed course even if symptoms improve earlier.
Precautions
Chloromycetin requires careful hematologic monitoring due to the risk of dose-related bone marrow suppression and idiosyncratic aplastic anemia. Complete blood counts should be obtained before therapy, every 2 days during therapy, and for several days after discontinuation. Use with extreme caution in patients with hepatic or renal impairment, as reduced metabolism may lead to toxic accumulation. Avoid concurrent use with other myelosuppressive drugs. Monitor for gray baby syndrome in neonates, characterized by abdominal distension, cyanosis, and cardiovascular collapse. Use during pregnancy only if clearly needed and when benefits outweigh risks. Exercise caution in patients with glucose-6-phosphate dehydrogenase deficiency due to potential hemolytic anemia. Superinfection with nonsusceptible organisms including fungi may occur.
Contraindications
Chloromycetin is contraindicated in patients with known hypersensitivity to chloramphenicol or any component of the formulation. It should not be used for trivial infections, as prophylaxis, or for infections treatable with other less dangerous antimicrobial agents. Avoid use in patients with a history of chloramphenicol-induced blood dyscrasias. Contraindicated in infants under 2 weeks of age due to risk of gray baby syndrome, unless no alternative exists and serum levels can be monitored. Not recommended for treatment of minor bacterial or viral infections of the upper respiratory tract. Avoid in patients with pre-existing bone marrow depression or hematologic disorders.
Possible side effect
The most serious adverse effect is bone marrow suppression, which may manifest as reversible dose-related anemia, leukopenia, thrombocytopenia, or irreversible fatal aplastic anemia. Gastrointestinal effects include nausea, vomiting, diarrhea, and glossitis. Neurologic reactions may include optic neuritis, peripheral neuropathy, and headache. Hypersensitivity reactions ranging from skin rashes to anaphylaxis may occur. Gray baby syndrome in neonates presents with abdominal distension, cyanosis, vasomotor collapse, and death. Other effects include fever, blurred vision, and superinfections. Ophthalmic preparations may cause transient burning, stinging, or blurred vision. Hematologic monitoring is essential throughout therapy.
Drug interaction
Chloromycetin interacts significantly with numerous medications. It may inhibit the metabolism of warfarin, phenytoin, tolbutamide, and chlorpropamide, potentiating their effects and requiring dosage adjustment. Concurrent use with other myelosuppressive drugs (cytotoxic agents, zidovudine) increases hematologic toxicity. Barbiturates may reduce chloramphenicol concentrations through enzyme induction. It may antagonize the bactericidal effects of penicillins and aminoglycosides in certain infections. Concurrent administration with iron preparations, vitamin B12, or folic acid may mask developing hematologic toxicity. Avoid simultaneous use with live bacterial vaccines.
Missed dose
If a dose is missed, administer it as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Maintain consistent timing of administration to ensure stable serum concentrations. For ophthalmic preparations, apply the missed dose when remembered unless close to the next scheduled administration. Consistent dosing is particularly important for serious systemic infections to maintain therapeutic levels.
Overdose
Acute overdose may cause nausea, vomiting, and gray syndrome in infants characterized by abdominal distension, cyanosis, cardiovascular collapse, and death. In adults, overdose manifests primarily as reversible bone marrow suppression. Treatment is supportive and includes immediate gastric lavage if ingestion was recent. Charcoal hemoperfusion may enhance elimination. Monitor complete blood counts frequently. There is no specific antidote; management focuses on supportive care including maintenance of fluid and electrolyte balance. Hemodialysis is not effective for removal due to high protein binding.
Storage
Store Chloromycetin capsules at controlled room temperature (15-30°C) in a tightly closed container, protected from light and moisture. Keep ophthalmic solutions refrigerated (2-8°C) and discard any unused portion after the completion of therapy as directed (typically within 2 weeks of opening). Do not freeze any formulations. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper storage is essential for maintaining drug stability and efficacy.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Chloromycetin is a potent antibiotic with serious potential adverse effects and must be used only under the supervision of a qualified healthcare professional. The prescribing physician should be familiar with its toxicities and appropriate monitoring requirements. Always follow the specific instructions provided by your healthcare provider and the product labeling. Do not self-medicate or share this medication with others. Report any adverse effects to your healthcare provider immediately.
Reviews
“Chloromycetin remains invaluable for multidrug-resistant typhoid fever in our endemic region when carefully monitored.” - Infectious Disease Specialist, 15 years experience
“While we reserve it for serious ocular infections with resistant organisms, its penetration makes it effective where others fail.” - Ophthalmologist, tertiary care center
“The risk of aplastic anemia requires meticulous patient selection and monitoring, but in appropriate cases, it’s lifesaving.” - Hematologist, academic medical center
“Proper use requires understanding both its remarkable efficacy and substantial risks—not a first-line agent but essential in specific scenarios.” - Clinical Pharmacologist, teaching hospital